Using ASMA immunofluorescent staining data from SSc dermal fibroblasts isolated from clinically affected or non-affected skin area from 6 different donors and transduced with shRNAs targeting either ASMA or GFP (negative control), we evaluated how well the assay could measure inhibition of ASMA expression. This evidence concerns the gene ACTA1 and systemic sclerosis.